We were all children once.
And the children we once were stay with us for life.
Industry spends more money to develop technologies that address the last month of life, than on technologies that can transform a lifetime.Impact1 & i4KIDS Pediatric Innovation Hub, Stanford Biodesign (2024)
What begins in childhood shapes a lifetime.
Children are a quarter of the world's population, yet they receive only a small fraction of medical innovation. SCVC was built to change that.
Approach
From unmet need to global impact.
We invest globally in companies tackling the biggest problems in children's health, often with a path into larger adult markets.
* Access to Clalit's longitudinal health data spanning three decades of multi-modal records on millions of people, following health from childhood into adulthood, with an AI-driven data-science engine that dramatically accelerates insight discovery. All data use is subject to regulatory and ethics approvals, data governance and privacy safeguards.
Portfolio
And it's already happening.
Pioneering large-scale production of intact, functional mitochondria to transform human health. First-in-human expected at Schneider in 2027, for children with primary mitochondrial disease.
Winning takes more than capital.
Built for returns. Designed to transform healthcare.
Our pediatric-first approach, with privileged clinical, data and AI capabilities, creates a differentiated investment opportunity: finding overlooked innovation, validating it in real clinical settings, and unlocking value across pediatric and adult markets.
Team
The people behind SCVC.
Management team
Head of Innovation, Schneider
Clinical, innovation and operations

Advisory board

Chairman, Dor Group







Former Global President, J&J Spine










